Zanframundo Grazia, Graziani Alessandro, Barbara Caroli, Francesco Palmese, Teresa Minguzzi Maria, Cristian Cataleta, Pierluigi Graziani, Ludovico Domenicali
Department of Internal Medicine, S. Maria delle Croci Hospital Ravenna, Italy.
Radiology, S. Maria delle Croci Hospital Ravenna.
J Community Hosp Intern Med Perspect. 2021 Jun 21;11(4):470-472. doi: 10.1080/20009666.2021.1921908.
Novel Coronavirus disease (COVID-19) has been widely described as the cause for a proinflammatory and hypercoagulable state. The inflammatory process involving the alveolar vascular endothelium in the respiratory system, is a determining factor for the onset of primary Pulmonary Artery Thrombosis (PAT) even in patients with heparin prophylactic treatment. Little is known about the efficacy of the anticoagulant therapy during the course of PAT caused by COVID-19. In this paper we describe the results obtained in patients with moderate COVID-19 disease, previously threated with prophylactic enoxaparin, who then received full Anticoagulant treatment after diagnosis of PAT. After three months Computed Tomography Pulmonary Angiography demonstrated a complete resolution of the vascular obstructive lesions in all patients, while all the coagulation tests were normal.
新型冠状病毒病（COVID-19）已被广泛描述为促炎和高凝状态的病因。呼吸系统中涉及肺泡血管内皮的炎症过程，即使在接受肝素预防性治疗的患者中，也是原发性肺动脉血栓形成（PAT）发病的决定性因素。关于COVID-19引起的PAT病程中抗凝治疗的疗效知之甚少。在本文中，我们描述了中度COVID-19疾病患者的结果，这些患者先前接受了预防性依诺肝素治疗，在诊断为PAT后接受了全剂量抗凝治疗。三个月后，计算机断层扫描肺动脉造影显示所有患者的血管阻塞性病变完全消退，而所有凝血试验均正常。
